Siemens unveils new tools for efficient design of complex integrated circuits

Anthony Casciano President and CEO Siemens Financial Services
Anthony Casciano President and CEO - Siemens Financial Services
0Comments

Siemens has announced the release of its Innovator3D IC solution suite, which aims to enhance the design and analysis of complex, heterogeneously integrated 3D integrated circuits (ICs). This suite offers a streamlined approach for planning and integration, along with implementation of substrates and interposers, interface protocol compliance analysis, and management of design data. It features an AI-enhanced user experience that supports extensive multithreading and multicore capabilities.

The Innovator3D IC solution suite includes several components: the Innovator3D IC Integrator for constructing digital twins using a unified data model; the Innovator3D IC Layout solution for implementing package interposers and substrates; the Innovator3D IC Protocol Analyzer for analyzing chiplet-to-chiplet and die-to-die interface compliance; and the Innovator3D IC Data Management solution for managing designs in progress.

To address challenges posed by thinner dies and higher processing temperatures in 2.5D/3D IC architectures, Siemens introduced Calibre 3DStress. This tool provides accurate transistor-level analysis, verification, and debugging of thermo-mechanical stresses within 3D IC packaging. By allowing designers to assess chip-package interactions early in development, Calibre 3DStress helps prevent future failures while optimizing design performance and durability.

Building on Calibre 3DThermal’s launch in 2024, Calibre 3DStress extends Siemens’ Multiphysics solutions by reducing thermo-mechanical impacts. Unlike other stress analysis tools at the package level, it detects transistor-level stress to ensure that neither packaging processes nor product functionalities compromise circuit performance.

Customer feedback highlights positive experiences with Siemens’ technologies. Bryan Black, CEO of Chipletz stated: “In 2023, we adopted Siemens’ technology to meet the complex design and integration challenges of our advanced platform solutions. The Innovator3D IC solution suite plays a critical role in enabling the high-performance solutions we deliver to AI and HPC datacenters.” Similarly, Sandro Dalle Feste from STMicroelectronics commented on their use of Calibre 3DStress: “Siemens EDA’s Calibre 3DStress tool can synthesize the complexity of components…and create accurate IP-level stress analysis…The result is improved reliability and quality together with a reduced time to market.”

For more information about Siemens’ solutions for 2.5D/3DIC architectures, interested parties are encouraged to visit their website.

Siemens Digital Industries Software continues to support organizations in digital transformation through software, hardware, and services from its Xcelerator business platform. Their comprehensive digital twin technology aids companies in optimizing design processes across various industries.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.